The Los Angeles Times recently published a story highlighting the difficulties many people with CF face in covering the costs of care, even with health insurance. The article describes one family's struggle to deal with the skyrocketing cost of the critical CF therapy, Pulmozyme. (For that family, the cost of the drug rose from $30 to $784 a month.)

People with CF are living longer than ever before, yet an increasing number of people now face the issue of under-insurance, that is, health insurance coverage that is not adequate to afford the life-sustaining and life-lengthening care now available to them.

Learn more about what you can do to help educate lawmakers about the importance of access to care for people with CF.